Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.
Diffuse Large B-Cell Lymphoma Refractory
DRUG: Lenalidomide|DRUG: Ifosfamide|DRUG: Carboplatin|DRUG: Etoposide
Complete response rate, 12 weeks
Progression free survival rate, 1 year|Overall survival rate, 1 year|Overall response rate, 12 weeks|Safety as assessed using CTCAE v4.0, 1 year
This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.